肌层浸润性膀胱癌分期骨扫描后的下游检查研究
利用SEER-Medicare数据识别2004至2011年诊断的4404例肌层浸润性膀胱癌患者,其中1373例(31%)在治疗前接受分期骨扫描,26%接受了后续下游检查。接受下游检查者较未接受者治疗延迟一个月(P < 0.001),所有下游检查总费用为103468美元。作者认为常规使用该分期方式存在潜在劣势。
要点
- 肌层浸润性膀胱癌患者中31%接受分期骨扫描,其中26%需下游检查。
- 下游检查包括骨X线、骨CT、骨MRI和骨活检,骨活检罕见(n < 11;<1%)。
- 接受下游检查者治疗延迟一个月(P < 0.001),下游检查总费用103468美元。
核心结论
- 肌层浸润性膀胱癌分期使用骨扫描常导致需要额外下游检查,治疗延迟和费用负担凸显常规使用该分期方式的潜在劣势。
研究设计与样本
- 利用监测、流行病学和最终结果(SEER)-Medicare数据,识别2004至2011年诊断的4404例肌层浸润性膀胱癌患者。
- 进一步识别在诊断后6个月内、任何膀胱切除术、放疗或化疗前接受骨扫描的患者。
- 确定在骨扫描后3个月内且治疗前接受后续检查(骨X线、骨CT、骨MRI和/或骨活检)的患者比例。
主要发现
- 4404例肌层浸润性膀胱癌患者中,1373例(31%)接受了分期骨扫描。
- 接受骨扫描的患者中,26%(n = 213)接受了下游检查。
- 61例(7%)接受了骨特异性X线,超过141例(>17%)接受了骨特异性CT,28例(3%)接受了骨特异性MRI。
- 骨活检使用罕见(n < 11;<1%)。
- 所有下游检查总费用为103468美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the use of downstream studies following staging bone scans in patients with muscle-invasive bladder cancer. Bone scans may be obtained in high-risk bladder cancer patients prior to radical cystectomy to exclude bone metastases. However, false-positive bone scans can occur, resulting in the need for additional studies. PATIENTS AND METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified 4404 patients diagnosed with muscle-invasive bladder cancer from 2004 to 2011. We further identified those who underwent a bone scan prior to treatment within 6 months of diagnosis and prior to any treatment with cystectomy, radiotherapy, or chemotherapy. We determined the proportion of patients who underwent a subsequent study (bone X-ray, bone CT, bone MRI, and/or bone biopsy) within 3 months of the bone scan and prior to treatment. RESULTS: Among patients diagnosed with muscle-invasive bladder cancer, 1373 (31%) had a staging bone scan of whom 26% received a downstream study (n = 213). Overall, 61 patients (7%) received downstream bone-specific X-rays, more than 141 patients (>17%) received bone-specific CTs, and 28 patients (3%) received bone-specific MRIs. The use of bone biopsy was rare (n < 11; <1%). The total cost of all downstream studies was $103,468. Furthermore, there was a one-month delay in treatment for those who received a downstream study compared to those who did not (P < 0.001). CONCLUSION: Use of bone scan in the staging of muscle-invasive bladder cancer often results in the need for additional downstream studies. The delay in treatment and cost burden of downstream studies highlights a potential disadvantage of the routine use of this staging modality.
引用
- Maganty A, Turner RM, Yabes JG, et al. Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer. Urology. 2019. PMID: 31005656. doi:10.1016/j.urology.2019.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。